Melfalano Eugia

Melphalan, the active ingredient in Melfalano Eugia, is an alkylating agent presented as an injectable solution for intra‑arterial and intravenous use. It is employed in the treatment of certain hematologic and solid tumours, particularly in adult patients with multiple myeloma, ovarian cancer or malignant melanoma.

GNH USA supplies Melfalano Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use.

Melphalan is used as an antineoplastic agent targeting rapidly dividing cancer cells in several malignancies.

- Multiple myeloma: reduces tumor burden and prolongs survival in patients with relapsed or refractory disease. - Ovarian cancer: contributes to tumor shrinkage and improves response rates when combined with other chemotherapeutics. - Malignant melanoma: provides cytoreductive activity in advanced‑stage disease, often as part of combination regimens.

Melphalan may cause a range of adverse reactions, varying from mild to severe, that are monitored during therapy.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring during or after infusion. - Bone marrow suppression: decreased white blood cells, red cells, and platelets. - Fatigue: generalized tiredness affecting daily activities. - Alopecia: temporary hair loss on scalp and body.

Serious or Rare Side Effects: - Secondary malignancies: development of new cancers such as leukemia. - Severe infection: opportunistic infections due to profound neutropenia. - Pulmonary fibrosis: progressive scarring of lung tissue leading to respiratory compromise.

Prior to initiating melphalan therapy, clinicians should evaluate patient history and implement safety measures to minimize risks.

- Baseline blood counts: obtain complete blood count to assess marrow function before each cycle. - Renal function: monitor serum creatinine and adjust dosing in patients with impaired clearance. - Pregnancy and lactation: avoid use in pregnant or breastfeeding women unless benefits outweigh risks. - Concomitant myelosuppressive agents: use caution when combined with other chemotherapy that depresses bone marrow. - Store at ambient temperature: keep vials below 25 °C, protect from light and moisture, and retain in original packaging.

Melphalan can interact with other medicines, altering its efficacy or increasing toxicity; awareness of key interactions guides safe prescribing.

Major Interactions (Avoid): - Live vaccines: concurrent administration may cause uncontrolled infection due to immunosuppression. - Strong CYP450 inducers: agents such as rifampin can reduce melphalan plasma levels, diminishing therapeutic effect.

Moderate Interactions (Monitor Closely): - Antifungal azoles: may increase melphalan exposure and heighten myelosuppression risk. - Allopurinol: can potentiate hematologic toxicity; monitor blood counts closely. - NSAIDs: may exacerbate renal impairment when used with melphalan; assess renal function regularly.